Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

This study is using artificial intelligence (AI) to help guide treatment decisions for adults with neovascular ("wet") age-related macular degeneration (AMD) — a leading cause of vision loss in older adults. Researchers will track how well patients do when their eye injections (anti-VEGF treatments) are managed using AI tools in a real-world clinical setting. You may be eligible if: - You are 50 years of age or older - You have active neovascular (wet) AMD in one eye, confirmed by imaging tests - Your vision in the study eye is at least 20/200 or better - You are willing to follow up with scheduled appointments You may NOT be eligible if: - You have a known allergy to fluorescein dye or the eye injection medications (ranibizumab, aflibercept, or brolucizumab) - You have had eye surgery in the study eye within the last 3 months - You have uncontrolled glaucoma in the study eye - You have active eye infections or inflammation - You have a retinal detachment or macular hole history in the study eye Talk to your doctor to see if this trial is right for you.